Skip to content
Boost Up Blog – Lifestyle
Author:
Fractyl Health, Inc.
Fractyl Health Reports Positive Randomized Data from REMAIN-1 Midpoint Cohort Demonstrating Durable Weight Maintenance One Year After GLP-1 Discontinuation
July 15, 2026
Fractyl Health Reports Positive One-Year REVEAL-1 Open-Label Results Showing Sustained Post-GLP-1 Weight Maintenance After a Single Revita® Procedure
June 4, 2026
Fractyl Health Appoints Mike Zumdahl as Senior Vice President, Market Access and Commercial Strategy
June 1, 2026
Fractyl Health Reports First Quarter 2026 Financial Results and Business Updates
May 20, 2026
Fractyl Health Authorized to Initiate First-in-Human Trial of RJVA-001 in the Netherlands: First Gene Therapy Candidate to Enter Clinical Development for Type 2 Diabetes
May 11, 2026
←
Previous Page
1
2